IN2015DN02255A - - Google Patents

Info

Publication number
IN2015DN02255A
IN2015DN02255A IN2255DEN2015A IN2015DN02255A IN 2015DN02255 A IN2015DN02255 A IN 2015DN02255A IN 2255DEN2015 A IN2255DEN2015 A IN 2255DEN2015A IN 2015DN02255 A IN2015DN02255 A IN 2015DN02255A
Authority
IN
India
Prior art keywords
ntibody
formulations
low viscosity
especially high
prolactin receptor
Prior art date
Application number
Inventor
Xinghang; Ma
Jun; Xiang
Jianjie; Niu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2015DN02255A publication Critical patent/IN2015DN02255A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are a wide concentration range , especially high concentration substantially salt- free anti- prolactin receptor a,ntibody formulations that are substantially isosmotic and of low viscosity.
IN2255DEN2015 2012-08-31 2013-08-28 IN2015DN02255A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695949P 2012-08-31 2012-08-31
US13/842,906 US8883979B2 (en) 2012-08-31 2013-03-15 Anti-prolactin receptor antibody formulations
PCT/US2013/056976 WO2014036076A1 (en) 2012-08-31 2013-08-28 Anti-prolactin receptor antibody formulations

Publications (1)

Publication Number Publication Date
IN2015DN02255A true IN2015DN02255A (en) 2015-08-21

Family

ID=49162240

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2255DEN2015 IN2015DN02255A (en) 2012-08-31 2013-08-28

Country Status (30)

Country Link
US (4) US8883979B2 (en)
EP (1) EP2890397B1 (en)
JP (1) JP6444871B2 (en)
KR (1) KR102100282B1 (en)
CN (3) CN111202844A (en)
AR (2) AR092387A1 (en)
AU (1) AU2013308907B2 (en)
BR (1) BR112015004397B1 (en)
CA (1) CA2883097C (en)
CY (1) CY1121990T1 (en)
DK (1) DK2890397T3 (en)
ES (1) ES2742868T3 (en)
HK (1) HK1207316A1 (en)
HR (1) HRP20191199T1 (en)
HU (1) HUE045494T2 (en)
IL (1) IL237277B (en)
IN (1) IN2015DN02255A (en)
LT (1) LT2890397T (en)
MX (1) MX367691B (en)
NZ (1) NZ705178A (en)
PL (1) PL2890397T3 (en)
PT (1) PT2890397T (en)
RS (1) RS59207B1 (en)
RU (1) RU2649372C2 (en)
SG (1) SG11201501225SA (en)
SI (1) SI2890397T1 (en)
TW (3) TW201422235A (en)
UY (2) UY34994A (en)
WO (1) WO2014036076A1 (en)
ZA (1) ZA201501279B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2867265C (en) 2012-03-14 2024-01-02 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
SG11201504943QA (en) 2012-12-24 2015-07-30 Abbvie Inc Prolactin receptor binding proteins and uses thereof
JP2016515515A (en) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Anti-prolactin receptor antibody preparation
CN107513105B (en) 2013-05-30 2019-08-16 基尼克萨制药有限公司 Oncostatin M receptor antigen binding proteins
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
AR103173A1 (en) * 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
SI3256154T1 (en) * 2015-02-09 2020-02-28 UCB Biopharma SRL Pharmaceutical formulation comprising antibody
AU2016289480C1 (en) 2015-07-06 2021-10-21 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
EP3769781B1 (en) 2015-08-19 2023-04-19 Astrazeneca AB Stable anti-ifnar1 formulation
TW201726111A (en) * 2015-09-30 2017-08-01 持田製藥股份有限公司 Liquid pharmaceutical agent comprising high concentration antibody
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
TWI761453B (en) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 Anti-rsv monoclonal antibody formulation
WO2018179138A1 (en) * 2017-03-29 2018-10-04 持田製薬株式会社 Antibody-containing liquid preparation
TW201836647A (en) 2017-04-06 2018-10-16 美商艾伯維有限公司 Anti-prlr antibody-drug conjugates (adc) and uses thereof
WO2018191414A1 (en) 2017-04-11 2018-10-18 Kiniksa Pharmaceuticals, Ltd. Stable anti-osmr antibody formulation
BR112019022873A8 (en) 2017-05-02 2023-04-11 Merck Sharp & Dohme FORMULATION, AND, INJECTION VESSEL OR DEVICE.
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112020000378A2 (en) 2017-07-10 2020-07-21 Bayer Pharma Aktiengesellschaft prolactin receptor antibody for male and female standard hair loss
JP7183268B2 (en) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド Aflibercept formulation containing lysine salt as tonicity agent and its use
KR20200118151A (en) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for delivery of therapeutic proteins
KR20210062027A (en) * 2018-09-13 2021-05-28 에프. 호프만-라 로슈 아게 CSF-1R antibody preparation
CA3115708A1 (en) * 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
CA3118282A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
KR20210141592A (en) * 2019-03-21 2021-11-23 리제너론 파아마슈티컬스, 인크. Stabilized Formulations Containing Anti-IL-33 Antibodies
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
WO2023230532A1 (en) * 2022-05-26 2023-11-30 Compugen Ltd. Anti-tigit antibody formulation

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
ATE230277T1 (en) 1997-06-13 2003-01-15 Genentech Inc STABILIZED ANTIBODY FORMULATION
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
HU227347B1 (en) 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
SI2371392T1 (en) 2002-05-02 2015-10-30 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
HUE037603T2 (en) 2002-06-21 2018-09-28 Novo Nordisk Healthcare Ag Stabilised solid compositions of factor VIIa polypeptides
CN1751236A (en) * 2002-12-16 2006-03-22 健泰科生物技术公司 Transgenic mice expressing human CD20
JP4728948B2 (en) 2003-02-10 2011-07-20 エラン ファーマシューティカルズ，インコーポレイテッド Immunoglobulin preparation and method for its preparation
BRPI0408439A (en) 2003-03-18 2006-04-04 Novo Nordisk Healthcare Ag aqueous liquid pharmaceutical composition, method for preparing and using same, method for treating a factor responsive syndrome vii, and, airtight container
CN1780637A (en) 2003-03-18 2006-05-31 诺和诺德医疗保健公司 Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2609010T3 (en) 2003-04-04 2017-04-18 Genentech, Inc. Antibody and protein formulations at high concentration
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CA2737127C (en) 2003-05-14 2016-07-26 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
RU2364609C2 (en) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Stabilisation of protein in solution
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ATE446768T1 (en) 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES
BRPI0413518A (en) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag aqueous liquid pharmaceutical composition, method for preparing and using same, method for treating a factor responsive syndrome vii, and, airtight container
SI1698640T2 (en) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
DE10361599A1 (en) 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Liquid formulation of antibody conjugates
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022927A1 (en) 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-linked sucrose derivatives for the stabilization of antibodies or antibody derivatives
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP2008519032A (en) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Formulation, production method and use of FGF-20
DE102005002353A1 (en) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg Use of receptor multimerization epitope (RME) of advanced glycation end product receptor (AGER) as immunogen, useful for preparing antibodies for diagnosis and treatment of e.g. spinal injuries or diabetic complications
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
WO2007002543A2 (en) * 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CA2612937C (en) 2005-07-22 2014-05-06 Amgen Inc. Concentrated protein lyophilates, methods, and uses
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
BRPI0707796A2 (en) 2006-02-15 2011-05-10 Imclone Systems Inc formulation and treatment method
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
BRPI0715718A2 (en) * 2006-08-18 2014-06-24 Novartis Ag ANTIBODY, METHODS OF TRIARING TO AN ANTIBODY FOR THE EXTRACELLULAR DOMAIN OF A PRLR PROTEIN, SYSTEMATICALLY CHANGING ANTIBODIES AND TRIATING TO AN ANTIBODY FOR AN EXTRACELLULAR DOMAIN, OF A CURREN ALTERNATE EXPRESSA PRLR, TO USE A HOSPITAL CELL, TO IDENTIFY AN INDIVIDUAL OF TREATMENT WITH AN ANTI-PRLR ANTIBODY, AND TO MONITOR CANCER THERAPY IN AN INDIVIDUAL, ISOLATED NUCLEIC ACID COMPLETE MOLECULES And, KIT
WO2008039761A2 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
US20110070225A1 (en) * 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
JP5558106B2 (en) 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー Subcutaneous administration of coagulation factor VII-related polypeptide
CN101674847A (en) 2007-05-02 2010-03-17 弗·哈夫曼-拉罗切有限公司 Method for stabilizing a protein
US20100189721A1 (en) 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
MX2010001723A (en) 2007-08-17 2010-04-30 Amgen Inc Formulations of antibodies and fc-fusion molecules using polycations.
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
JP5840364B2 (en) 2007-11-30 2016-01-06 アッヴィ バイオテクノロジー リミテッド Protein preparation and method for producing the same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101896163A (en) * 2007-12-21 2010-11-24 弗·哈夫曼-拉罗切有限公司 Antibody formulation
US20100285051A1 (en) * 2007-12-21 2010-11-11 Dominique Ingrid Lemoine Vaccine
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
EP2235042A1 (en) 2008-01-23 2010-10-06 Novo Nordisk Health Care AG New blood coagulation factor inhibitors
AU2009313754A1 (en) 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
EP2350649A4 (en) * 2008-11-28 2012-11-14 Abbott Lab Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
RS61082B1 (en) 2010-02-26 2020-12-31 Novo Nordisk As Stable antibody containing compositions
JP5918246B2 (en) * 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Stabilized preparation containing anti-interleukin-4 receptor (IL-4R) antibody

Also Published As

Publication number Publication date
RU2649372C2 (en) 2018-04-02
TW201422235A (en) 2014-06-16
SG11201501225SA (en) 2015-03-30
RU2015111319A (en) 2016-10-20
CN104736175A (en) 2015-06-24
AU2013308907B2 (en) 2018-04-19
UY34999A (en) 2014-03-31
TWI688404B (en) 2020-03-21
JP2015528465A (en) 2015-09-28
BR112015004397A2 (en) 2017-12-19
AR092401A1 (en) 2015-04-22
KR102100282B1 (en) 2020-04-13
CN111202844A (en) 2020-05-29
IL237277B (en) 2020-04-30
EP2890397A1 (en) 2015-07-08
DK2890397T3 (en) 2019-08-05
UY34994A (en) 2014-03-31
PT2890397T (en) 2019-09-10
CA2883097A1 (en) 2014-03-06
BR112015004397B1 (en) 2022-07-19
CN111202843A (en) 2020-05-29
US8883979B2 (en) 2014-11-11
ES2742868T3 (en) 2020-02-17
HRP20191199T1 (en) 2019-10-18
ZA201501279B (en) 2016-11-30
US20150252116A1 (en) 2015-09-10
LT2890397T (en) 2019-09-25
US20150093393A1 (en) 2015-04-02
IL237277A0 (en) 2015-04-30
NZ705178A (en) 2018-06-29
HUE045494T2 (en) 2019-12-30
PL2890397T3 (en) 2019-12-31
US20170008965A1 (en) 2017-01-12
CN104736175B (en) 2019-11-01
AU2013308907A1 (en) 2015-03-12
TW201821103A (en) 2018-06-16
AR092387A1 (en) 2015-04-22
TW201414491A (en) 2014-04-16
CY1121990T1 (en) 2020-10-14
US20140065158A1 (en) 2014-03-06
EP2890397B1 (en) 2019-06-19
RS59207B1 (en) 2019-10-31
SI2890397T1 (en) 2019-11-29
HK1207316A1 (en) 2016-01-29
MX367691B (en) 2019-09-02
JP6444871B2 (en) 2018-12-26
MX2015002412A (en) 2015-09-29
TWI641384B (en) 2018-11-21
WO2014036076A1 (en) 2014-03-06
KR20150046298A (en) 2015-04-29
CA2883097C (en) 2022-11-15

Similar Documents

Publication Publication Date Title
IN2015DN02255A (en)
SA518391159B1 (en) Affinity-Oligonucleotide Conjugates and Uses Thereof
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
HK1214499A1 (en) Stable, low viscosity antibody formulation
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
MX2015017331A (en) Anti-fcrh5 antibodies.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2015012334A (en) Methods and compositions for weed control.
UY34628A (en) ? MINERAL POWDER MATERIAL WITH HIGH DISPERSION CAPACITY, AND USE OF THIS MINERAL POWDER MATERIAL ?.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2018014178A (en) Anti-fgfr2 antibody.
MX2016004853A (en) ANTI-Ly6E ANTIBODIES AND METHODS OF USE.
IN2014MN02276A (en)
MX2016004802A (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses.
MY167801A (en) Oil-and/or-Fat Composition and Bakery Foods Using Oil-and/or-Fat Composition
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX353951B (en) Anti-theophylline antibodies and methods of use.
MX2015010789A (en) Anti-mcsp antibodies.
AU353234S (en) Oil pourer stem
UA54830U (en) Topinambour-carrot paste of functional purpose
UA73970U (en) Vegetable paste of functional purpose
CL2012003477S1 (en) Safety pin
AU353403S (en) Respirator